- Home
- BTBD vs BIVI Comparison
BTBD vs BIVI Comparison
Compare BTBD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | BIVI |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTBD | BIVI |
|---|---|---|
| Price | $1.28 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.6K | ★ 107.8K |
| Earning Date | 03-30-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,038,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.06 |
| 52 Week High | $5.60 | $18.75 |
Technical Indicators
Market Signals| Indicator | BTBD | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 55.77 |
| Support Level | $1.15 | $1.08 |
| Resistance Level | $1.30 | $1.21 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 41.95 | 75.81 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.